Dr. Tamer Hellou, MD, is an Assistant Professor of Medicine at the Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA.
He completed his Internal Medicine residency and Hematology fellowship in Israel, followed by advanced fellowship training in plasma cell disorders at Mayo Clinic in Rochester, Minnesota, focusing on multiple myeloma and AL amyloidosis.
His clinical and research interests include multiple myeloma, AL amyloidosis, plasma cell leukemia, immunotherapies, autologous stem cell transplantation, and prognostic biomarkers. His research focuses on plasma cell proliferation, cytogenetic risk stratification, and treatment outcomes in plasma cell malignancies. He has authored and co-authored peer-reviewed publications in these areas and is actively involved in clinical and translational research.
He is a member of the American Society of Hematology (ASH), European Hematology Association (EHA), International Myeloma Society (IMS), International Society of Amyloidosis (ISA), Israel Society of Hematology and Blood Transfusion, and Israel Society of Internal Medicine.
Dr. Tamer Hellou, MD, is an Assistant Professor of Medicine at the Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA.
He completed his Internal Medicine residency and Hematology fellowship in Israel, followed by advanced fellowship training in plasma cell disorders at Mayo Clinic in Rochester, Minnesota, focusing on multiple myeloma and AL amyloidosis.
His clinical and research interests include multiple myeloma, AL amyloidosis, plasma cell leukemia, immunotherapies, autologous stem cell transplantation, and prognostic biomarkers. His research focuses on plasma cell proliferation, cytogenetic risk stratification, and treatment outcomes in plasma cell malignancies. He has authored and co-authored peer-reviewed publications in these areas and is actively involved in clinical and translational research.
He is a member of the American Society of Hematology (ASH), European Hematology Association (EHA), International Myeloma Society (IMS), International Society of Amyloidosis (ISA), Israel Society of Hematology and Blood Transfusion, and Israel Society of Internal Medicine.